Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 600
- 试验地点
- 6
- 主要终点
- Event-free survival after induction therapy
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab ozogamicin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether cytarabine and daunorubicin followed by gemtuzumab ozogamicin is more effective than cytarabine and daunorubicin in treating acute myeloid leukemia or myelodysplastic syndromes.
PURPOSE: This randomized phase III trial is studying cytarabine and two different doses of daunorubicin to see how well they work compared to cytarabine and daunorubicin followed by gemtuzumab ozogamicin in treating older patients with acute myeloid leukemia or myelodysplastic syndromes.
详细描述
OBJECTIVES:
Primary
- Compare the event-free and disease-free survival of older patients with acute myeloid leukemia, refractory anemia with excess blasts (RAEB), or RAEB in transformation treated with induction therapy comprising cytarabine in combination with two different doses of daunorubicin followed by cytarabine alone with or without post-induction therapy comprising gemtuzumab ozogamicin.
Secondary
- Compare the complete remission rate in patients treated with these regimens.
- Compare the overall survival of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Determine the probability of relapse and death during first complete remission in patients treated with post-induction gemtuzumab ozogamicin.
- Correlate prognostic factors (e.g., CD33 positivity, multidrug resistance phenotype, or cytogenetics) with probability of complete remission and overall, event-free, and disease-free survival of patients treated with these regimens.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 61 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Arm A low dose Dauno
Induction 45 mg Dauno
干预措施: cytarabine (Drug)
Arm A low dose Dauno
Induction 45 mg Dauno
干预措施: daunorubicin hydrochloride (Drug)
ARM B high dose Dauno
Induction 90 mg Dauno
干预措施: cytarabine (Drug)
ARM B high dose Dauno
Induction 90 mg Dauno
干预措施: daunorubicin hydrochloride (Drug)
Arm 2 Mylotarg
Post induction treatment with Mylotarg
干预措施: gemtuzumab ozogamicin (Drug)
结局指标
主要结局
Event-free survival after induction therapy
Disease-free survival after maintenance therapy
次要结局
- Probability of relapse and death in first CR after maintenance therapy
- Overall survival after maintenance therapy
- Overall survival after induction therapy
- Complete remission (CR) rate after induction therapy
- Toxicity after induction therapy
- Toxicity after maintenance therapy